Flag of the European Union EU Clinical Trials Register Help

Clinical trials for - Crohn’s Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,518 result(s) found for: - Crohn’s Disease. Displaying page 892 of 1,426.
    «« First « Previous 888  889  890  891  892  893  894  895  896  Next» Last»»
    EudraCT Number: 2018-000802-46 Sponsor Protocol Number: D169CC00001 Start Date*: 2018-09-24
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failur...
    Medical condition: Heart Failure with Preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) PL (Completed) HU (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-004362-17 Sponsor Protocol Number: MITO-16b/MANGO-OV2b/ENGOT-OV17 Start Date*: 2013-01-20
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE 'G. PASCALE'
    Full Title: A multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemoth...
    Medical condition: platinum sensitive ovarian cancer patients progressing or recurring after a first-line treatment including bevacizumab.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GR (Completed) FR (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023484-17 Sponsor Protocol Number: 2010-023484-17 Start Date*: 2011-06-11
    Sponsor Name:ITALIAN SARCOMA GROUP
    Full Title: LOCALIZED HIGH-RISK SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL IN ADULTS: AN INTEGRATING APPROACH COMPRISING STANDARD VS HISTOTYPE-TAILORED NEOADJUVANT CHEMOTHERAPY (ISG-STS 10-01)
    Medical condition: High risk localized soft tissue sarcomas typical of the adult
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041299 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002869-35 Sponsor Protocol Number: CAPLAND Start Date*: 2020-03-10
    Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT)
    Full Title: A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung can...
    Medical condition: Advanced or metastatic untreated EGFR mutation positive NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002526-23 Sponsor Protocol Number: CS2514-2017-0004 Start Date*: 2019-05-07
    Sponsor Name:Entasis Therapeutics
    Full Title: A Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter baumannii-calcoacetic...
    Medical condition: Infections Caused by Acinetobacter baumannii-calcoaceticus Complex
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10003999 Bacteremia LLT
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    20.1 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    20.0 10021881 - Infections and infestations 10076918 Hospital acquired pneumonia LLT
    20.1 10021881 - Infections and infestations 10065153 Ventilator associated pneumonia LLT
    20.0 10021881 - Infections and infestations 10078408 Surgical site infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022890-33 Sponsor Protocol Number: EQol-MDS Start Date*: 2010-11-23
    Sponsor Name:ASSOCIAZIONE QOL-ONE
    Full Title: Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes.
    Medical condition: Adult patients with low or intermediate-1 IPSS risk MDS and thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035534 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Ongoing) SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002538-14 Sponsor Protocol Number: 218672 Start Date*: 2023-06-12
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: 17-beta-Hydroxysteroid Dehydrogenase type 13 Minimization for the treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002641-15 Sponsor Protocol Number: PBP-301 Start Date*: 2021-10-27
    Sponsor Name:Point BioPharma Inc.
    Full Title: SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment
    Medical condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001211-21 Sponsor Protocol Number: HO136 Start Date*: 2017-04-14
    Sponsor Name:HOVON Foundation
    Full Title: Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in fir...
    Medical condition: CD30 positive diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003061-19 Sponsor Protocol Number: CL1-65487-003 Start Date*: 2021-01-07
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multi-centre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl...
    Medical condition: Previously untreated Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) FR (Trial now transitioned) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000783-29 Sponsor Protocol Number: GBR830-204 Start Date*: 2018-12-18
    Sponsor Name:Ichnos Sciences SA
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects with Moderate to Severe Atopic Dermatitis.
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000439-14 Sponsor Protocol Number: CMBG453C12201 Start Date*: 2021-03-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II multi-center, single arm, safety and efficacy study of MBG453 in combination with azacitidine and venetoclax for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for...
    Medical condition: Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000891-12 Sponsor Protocol Number: 212149 Start Date*: 2021-10-05
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A staged Phase I/II observer-blind, randomised, controlled, multi-country study to evaluate the safety, reactogenicity, and immune responses to the GVGH altSonflex1-2-3 vaccine against S. sonnei an...
    Medical condition: Prophylaxis for Shigellosis induced by Shigella sonnei, Shigella flexneri 1b, Shigella flexneri 2a and Shigella flexneri 3a.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040550 Shigella infections HLT
    20.0 10021881 - Infections and infestations 10054178 Shigella infection PT
    20.0 10021881 - Infections and infestations 10040542 Shigella LLT
    20.0 10021881 - Infections and infestations 10040547 Shigella flexneri LLT
    20.0 10021881 - Infections and infestations 10040551 Shigella sonnei LLT
    20.1 10021881 - Infections and infestations 10004016 Bacterial diarrhoea PT
    20.0 10017947 - Gastrointestinal disorders 10012735 Diarrhoea PT
    Population Age: Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-018006-21 Sponsor Protocol Number: 205.420 Start Date*: 2010-06-10
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase II, randomised, double- blind, placebo controlled, cross-over efficacy and safety comparison of tiotropium 5 μg administered once daily (in the evening) and tiotropium 2.5 μg administered t...
    Medical condition: moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) EE (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001149-25 Sponsor Protocol Number: FSS-AS-301 Start Date*: 2014-11-07
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 12-Week, Double-Blinded, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/ Salmeterol Multidose Dry Powder Inhaler i...
    Medical condition: Persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-012057-38 Sponsor Protocol Number: CQTI571A2301 Start Date*: 2009-08-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arteria...
    Medical condition: Pulmonary arterial hypertension (PAH) patients who have a PVR ≥800 dynes.sec.cm-5 despite treatment with two or more specific PAH therapies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Completed) FR (Completed) SE (Completed) BE (Completed) IT (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003088-23 Sponsor Protocol Number: M13-099 Start Date*: 2012-12-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adults with Genotype 1 Chroni...
    Medical condition: Chronic Hepatitis C Infection and compensated cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002885-38 Sponsor Protocol Number: HGT-HIT-094 Start Date*: 2013-10-22
    Sponsor Name:Shire HGT Inc
    Full Title: A Controlled,Randomized,Two-arm,Open-label,Assessor-blinded,Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Elaprase® in Pediatric Patients with Hunter Syndrome and...
    Medical condition: Long-term treatment of Hunter syndrome and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10056889 Mucopolysaccharidosis II PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001549-13 Sponsor Protocol Number: GB39242 Start Date*: 2016-12-16
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA
    Medical condition: Uncontrolled Severe Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10003560 Asthma NOS LLT
    19.0 100000004855 10015888 Extrinsic asthma LLT
    19.0 100000004855 10003561 Asthma, unspecified LLT
    19.0 100000004855 10001705 Allergic asthma LLT
    19.0 100000004855 10003554 Asthma aggravated LLT
    19.0 100000004855 10068393 Neutrophilic asthma LLT
    19.0 100000004855 10022847 Intrinsic asthma LLT
    19.0 100000004855 10074614 Nocturnal asthma LLT
    19.0 100000004855 10003638 Atopic asthma LLT
    19.0 100000004855 10068463 Paucigranulocytic asthma LLT
    19.0 100000004855 10009029 Chronic obstructive asthma (with obstructive pulmonary disease), w/o-ment of status asthmaticus LLT
    19.0 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-002785-10 Sponsor Protocol Number: 2005032 Start Date*: 2005-10-21
    Sponsor Name:Procter & Gamble Pharmaceuticals Inc
    Full Title: A Phase III, Multicenter, Double-Blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly with 5 mg Risedronate Daily in the Treatment of Pos...
    Medical condition: Osteoporosis in post-menopausal women
    Disease: Version SOC Term Classification Code Term Level
    7.0 10031285 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) FI (Completed) ES (Ongoing) EE (Completed) BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 888  889  890  891  892  893  894  895  896  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Feb 14 21:49:48 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA